Existing medication may hold the key in preventing breast cancer in women carrying a faulty BRCA1 gene.
Researchers from the Walter and Eliza Hall have identified that the drug denosumab may have potential to prevent breast cancer from developing.
Currently many women with a gene mutation choose surgical removal of their breast tissue and ovaries to reduce their chance of developing breast and ovarian cancer.
If confirmed in clinical studies, this would provide a non-surgical option to prevent breast cancer in women with elevated genetic risk.
Using samples of breast tissue donated by women carrying a faulty BRCA1 gene, Ms Emma Nolan, Professor Jane Visvader and Professor Geoff Lindeman were able to pinpoint the cells that give rise to breast cancer.
Ms Emma Nolan, PhD student at the Walter and Eliza Hall explained that the cancer precursor cells in BRCA1-mutant breast tissue had many similarities to aggressive forms of breast cancer.
“These cells proliferated rapidly, and were susceptible to damage to their DNA – both factors that help them transition towards cancer,” she said. “We were excited to discover that these pre-cancerous cells could be identified by a marker protein called RANK.”
Professor Lindeman, medical oncologist at The Royal Melbourne Hospital and Director-Designate of the Parkville Familial Cancer Centre, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.
“An inhibitor called denosumab is already used in the clinic to treat osteoporosis and breast cancer that has spread to the bone,” he said. “We therefore investigated what effect RANK inhibition had on the cancer precursor cells in BRCA1-mutant breast tissue.”
The research team showed that RANK inhibition switched off cell growth in breast tissue from women with a faulty BRCA1 gene and curtailed breast cancer development in laboratory models.
“We think this strategy could delay or prevent breast cancer in women with an inherited BRCA1 gene mutation,” Professor Lindeman said.
“A clinical trial at The Royal Melbourne Hospital has already begun to investigate this further.”
Professor Visvader said the discovery had its basis in more than a decade of investigations of breast stem cell function.
“By thoroughly dissecting how normal breast tissue develops, we have been able to pinpoint the precise cells that are the culprits in cancer formation,” she said.
“It is very exciting to think that we may be on the path to the ‘holy grail’ of cancer research, devising a way to prevent this type of breast cancer in women at high genetic risk.”
The research team worked closely with Mrs Avis Macphee, a patient advocate, through the Walter and Eliza Hall Institute’s consumer-researcher buddy system.
The research was supported by The National Breast Cancer Foundation, The Qualtrough Cancer Research Fund, The Joan Marshall Breast Cancer Research Fund, the Australian Cancer Research Foundation, Cancer Council Victoria, the Cancer Therapeutics Cooperative Research Centre, an Amgen Preclinical Research Program Grant, the National Health and Medical Research Council, the Victorian Cancer Agency, and the Victorian Government Operational Infrastructure Support Scheme.
The research, which also involved researchers at the Australian familial cancer consortium kConFab and US biotechnology company Amgen was published today in Nature Medicine.
* Photos courtesy of the Walter and Eliza Hall Institute